Amneal Pharmaceuticals, Inc. AMRX
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) is a CNS/neurology/psychiatry specialty pharmaceutical company.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CREXONT | CNS (Parkinson's disease focus per 10-K) | unclear | Approved |
| BREKIYA autoinjector | not stated in extract | device-combination | Approved |
| UNITHROID | endocrine (thyroid) | unclear | Approved |
| RYTARY | CNS (Parkinson's disease focus) | unclear | Approved |
| IPX203 (Europe, licensed to Zambon) | CNS | unclear | Approved |
Recent results and decisions
- Aug 10, 2026n/a Amneal completed acquisition of Kashiv BioSciences for $375 million cash, 28.9 million shares of Class A common stock, and up to $350 million in potential regulatory milestone payments for six designated product candidates plus tiered royalties.
Amneal LLC purchased from the Sellers 100% of the issued and outstanding membership interests of Kashiv for $375.0 million in cash and 28,942,108 shares of Class A Common Stock, with Sellers eligible to receive up to an additional $350.0 million in potential contingent payments upon achievement of c
Filing - Dec 31, 2025met Kashiv recognized $17.5 million of milestone revenue in 2025 related to additional developmental milestones under the Amneal license agreement for omalizumab biosimilar.
During the year ended December 31, 2025, Kashiv recognized $17.5 million of milestone revenue related to additional developmental milestones under this agreement.
Filing - Dec 16, 2025n/a Kashiv and Intas Pharmaceuticals signed an exclusive license agreement for Lanreotide in Europe and India with $1.2 million upfront and up to $23.5 million in milestone payments.
In connection with execution of the agreement, the Company was entitled to a nonrefundable upfront payment of $1.2 million and is eligible to receive future development, regulatory, launch, and sales-based milestone payments totaling up to approximately $23.5 million.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.